Metri Bio

Metri Bio is an early-stage biotech developing novel therapeutics for endometriosis and other endometrial diseases, addressing a massive unmet need in women's health. Founded in 2021, the company emerged from stealth in 2024 with a $5M pre-seed round and is built on a proprietary 3D endometrial modeling technology from the Sozen Lab at Yale. Led by a team with deep scientific and translational expertise, Metri Bio aims to move beyond symptomatic relief to discover and develop disease-modifying treatments. The company is currently expanding its team and R&D operations to advance its discovery platform and therapeutic programs toward preclinical studies.

Proprietary 3D endometrial organoid and disease modeling platform derived from Yale research. It enables the study of human endometrial biology and pathologies, like endometriosis, in a physiologically relevant in vitro system for novel target discovery and therapeutic development.

The endometriosis therapeutic landscape is evolving from generic hormones to novel mechanisms targeting inflammation, neuropathic pain, and angiogenesis. Competitors include biotechs like ObsEva (though restructured), AbbVie (investigating neurokinin antagonists), and many early-stage players. Metri Bio's key differentiation is its human-relevant discovery platform, aiming to identify entirely novel targets missed by traditional approaches.